Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-42756493 + Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT02952573Phase 2Terminated
- Sponsor
- University Health Network
- Start
- Jun 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of erdafitinib in multiple myeloma (MM) (2 arms), sponsored by University Health Network. Primary endpoints: Objective Response Rate at 5 years, Minimal Response Rate at 5 years and 1 more. Started Jun 2017; status: terminated.
02
Drugs
erdafitinib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02952573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02952573.